Is DT2216 legal in the United Kingdom?

The engineered answer to the navitoclax platelet problem: a degrader that hands BCL-xL to an E3 ligase platelets barely express. In the first human trial, 20 patients with solid tumours, only one dose-limiting toxicity occurred, a grade 4 thrombocytopenia that resolved within 48 hours.

Navitoclax kills senescent cells and platelets through the same target. DT2216 was designed around that.

Mechanism: Established in human cell lines and mice, with the intended platelet sparing now supported by human phase 1 data: DT2216 binds BCL-xL and recruits the VHL E3 ubiquitin ligase, marking BCL-xL for proteasomal degradation. Because VHL is minimally expressed in platelets, the degradation is inefficient there.

Regulatory history: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for DT2216 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.